{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:15:44Z","timestamp":1767212144282},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Children with Down syndrome (DS) show a high susceptibility to recurrent infections (RI), caused by immune defects and abnormalities of the airways. Our goal was to investigate the effects of Pidotimod on RI prevention in children with DS, comparing immune and clinical parameters before (T0) and after (T1) the treatment with Pidotimod.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The study was conducted at the Down syndrome outpatient Center of Bambino Ges\u00f9 Children\u2019s Hospital, in Rome. We reviewed the medical records of all children with a positive history for RI and who received oral prophylaxis of Pidotimod from September 2016 to February 2017.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Thirty-three children met the inclusion criteria (males: 51.5%; average age: 6\u2009years \u00b1SD: 3). We found a significant decrease in the number of children with upper respiratory infections (82% at T0 vs 24% at T1; <jats:italic>p<\/jats:italic>\u2009=\u20090,0001) and with lower respiratory infections (36% at T0 vs 9% at T1; <jats:italic>p<\/jats:italic>\u2009=\u20090.003) after treatment with Pidotimod. We also demonstrated a significant decrease in the number of children hospitalized for respiratory infections (18% at T0 vs 3% at T1; <jats:italic>p<\/jats:italic>\u2009=\u20090.03). We measured T and B cells in the peripheral blood and B cell function in vitro at T0 and T1. We found that the response to CpG improved at T1. A significant increase of B cell frequency (<jats:italic>p<\/jats:italic>\u2009=\u20090.0009), B cell proliferation (<jats:italic>p<\/jats:italic>\u2009=\u20090.0278) and IgM secretion (<jats:italic>p<\/jats:italic>\u2009=\u20090.0478) were observed in children with DS after treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our results provided evidence that Pidotimod may be able to prevent RI in children with Down syndrome.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13052-020-0797-5","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T05:32:03Z","timestamp":1584077523000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of Pidotimod on recurrent respiratory infections in children with Down syndrome: a retrospective Italian study"],"prefix":"10.1186","volume":"46","author":[{"given":"Diletta","family":"Valentini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Di Camillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Mirante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Marcellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Carsetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Villani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"key":"797_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/gim.2016.127","volume":"19","author":"G de Graaf","year":"2017","unstructured":"de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in the United States. Genet Med. 2017;19:439\u201347.","journal-title":"Genet Med"},{"key":"797_CR2","unstructured":"Mastroiacovo P, Diociaiuti L, Rosano A, Di Tanna GL. Epidemiology of Down syndrome in the third millenium. Med. 2002."},{"key":"797_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jpeds.2007.09.045","volume":"152","author":"ME Weijerman","year":"2008","unstructured":"Weijerman ME, van Furth AM, Vonk Noordegraaf A, van Wouwe JP, Broers CJ, Gemke RJ. Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a national study. J Pediatr. 2008;152:15\u20139.","journal-title":"J Pediatr"},{"key":"797_CR4","first-page":"23","volume":"29","author":"RH Chaney","year":"1985","unstructured":"Chaney RH, Eyman RK, Miller CR. The relationship of congenital heart disease and respiratory infection mortality in patients with Down\u2019s syndrome. J Ment Defic Res. 1985;29:23\u20137.","journal-title":"J Ment Defic Res"},{"key":"797_CR5","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1469-8749.1982.tb13702.x","volume":"24","author":"T Scholl","year":"1982","unstructured":"Scholl T, Stein Z, Hansen H. Leukemia and other cancers, anomalies and infections as causes of death in Down\u2019s syndrome in the United States during 1976. Dev Med Child Neurol. 1982;24:817\u201329.","journal-title":"Dev Med Child Neurol"},{"key":"797_CR6","first-page":"177","volume":"26","author":"ME Thase","year":"1982","unstructured":"Thase ME. Longevity and mortality in Down's syndrome. J Ment Defic Res. 1982;26:177\u201392.","journal-title":"J Ment Defic Res"},{"key":"797_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0140-6736(02)08092-3","volume":"359","author":"Q Yang","year":"2002","unstructured":"Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet. 2002;359:1019\u201325.","journal-title":"Lancet."},{"key":"797_CR8","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jpeds.2005.06.032","volume":"147","author":"MM Garrison","year":"2005","unstructured":"Garrison MM, Jeffries H, Christakis DA. Risk of death for children with Down syndrome and sepsis. J Pediatr. 2005;147:748\u201352.","journal-title":"J Pediatr"},{"key":"797_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.micinf.2010.05.007","volume":"12","author":"BL Bloemers","year":"2010","unstructured":"Bloemers BL, Broers CJ, Bont L, Weijerman ME, Gemke RJ, van Furth AM. Increased risk of respiratory tract infections in children with Down syndrome: the consequence of an altered immune system. Microbes Infect. 2010;12:799\u2013808.","journal-title":"Microbes Infect"},{"key":"797_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.imlet.2013.04.007","volume":"152","author":"F Capolunghi","year":"2013","unstructured":"Capolunghi F, Rosado MM, Sinibaldi M, Aranburu A, Carsetti R. Why do we need IgM memory B cells? Immunol Lett. 2013;152:114\u201320.","journal-title":"Immunol Lett"},{"key":"797_CR11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/eji.201445049","volume":"45","author":"R Carsetti","year":"2015","unstructured":"Carsetti R, Valentini D, Marcellini V, Scarsella M, Marasco E, Giustini F, Bartuli A, Villani A, Ugazio AG. Reduced numbers of switched memory B cells with high terminal differentiation potential in Down syndrome. Eur J Immunol. 2015;45:903\u201314.","journal-title":"Eur J Immunol"},{"key":"797_CR12","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.jaci.2013.10.010","volume":"133","author":"RH Verstegen","year":"2014","unstructured":"Verstegen RH, Borte S, Bok LA, van Zwieten PH, von D\u00f6beln U, Hammarstr\u00f6m L, de Vries E. Impact of Down syndrome on the performance of neonatal screening assays for severe primary immunodeficiency diseases. J Allergy Clin Immunol. 2014;133:1208\u201311.","journal-title":"J Allergy Clin Immunol"},{"key":"797_CR13","doi-asserted-by":"publisher","first-page":"6689","DOI":"10.1016\/j.vaccine.2015.10.083","volume":"33","author":"D Valentini","year":"2015","unstructured":"Valentini D, Marcellini V, Bianchi S, Villani A, Facchini M, Donatelli I, Castrucci MR, Marasco E, Farroni C, Carsetti R. Generation of switched memory B cells in response to vaccination in Down syndrome children and their siblings. Vaccine. 2015;33:6689\u201396.","journal-title":"Vaccine."},{"key":"797_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2249.2011.04335.x","volume":"164","author":"G Ram","year":"2011","unstructured":"Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011;164:9\u201316.","journal-title":"Clin Exp Immunol"},{"key":"797_CR15","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1542\/peds.2014-1666","volume":"134","author":"American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee","year":"2014","unstructured":"American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:620\u201338.","journal-title":"Pediatrics"},{"key":"797_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1542\/peds.2011-1605","volume":"128","author":"MJ Bull","year":"2011","unstructured":"Bull MJ. Committee on genetics. Health supervision for children with Down syndrome. Pediatrics. 2011;128:393\u2013406.","journal-title":"Pediatrics"},{"key":"797_CR17","first-page":"253","volume":"27","author":"GV Zuccotti","year":"2013","unstructured":"Zuccotti GV, Mameli C, Trabattoni D, Beretta S, Biasin M, Guazzarotti L, Clerici M. Immunomodulating activity of Pidotimod in children with Down syndrome. J Biol Regul Homeost Agents. 2013;27:253\u20138.","journal-title":"J Biol Regul Homeost Agents"},{"key":"797_CR18","first-page":"1473","volume":"44","author":"L D'Angelo","year":"1994","unstructured":"D'Angelo L, De Ponti F, Crema F, Caravaggi M, Crema A. Effect of food on the bioavailability of pidotimod in healthy volunteers. Arzneimittelforschung. 1994;44:1473\u20135.","journal-title":"Arzneimittelforschung."},{"key":"797_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1399-3038.2007.00625.x","volume":"18","author":"M de Martino","year":"2007","unstructured":"de Martino M, Ballotti S. The child with recurrent respiratory infections: normal or not? Pediatr Allergy Immunol. 2007;18:13\u20138.","journal-title":"Pediatr Allergy Immunol"},{"key":"797_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1399-3038.2007.00623.x","volume":"18","author":"N Principi","year":"2007","unstructured":"Principi N, Esposito S. New insights into pediatric rhinosinusitis. Pediatr Allergy Immunol. 2007;18:7\u20139.","journal-title":"Pediatr Allergy Immunol"},{"key":"797_CR21","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1542\/peds.2006-2881","volume":"119","author":"K Revai","year":"2007","unstructured":"Revai K, Dobbs LA, Nair S, Patel JA, Grady JJ, Chonmaitree T. Incidence of acute otitis media and sinusitis complicating upper respiratory tract infection: the effect of age. Pediatrics. 2007;119:1408\u201312.","journal-title":"Pediatrics"},{"key":"797_CR22","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1002\/eji.201343577","volume":"43","author":"MM Rosado","year":"2013","unstructured":"Rosado MM, Gesualdo F, Marcellini V, Di Sabatino A, Corazza GR, Smacchia MP, Nobili B, Baronci C, Russo L, Rossi F, Vito RD, Nicolosi L, Inserra A, Locatelli F, Tozzi AE, Carsetti R. Preserved antibody levels and loss of memory B cells against pneumococcus and tetanus after splenectomy: tailoring better vaccination strategies. Eur J Immunol. 2013;43:2659\u201370.","journal-title":"Eur J Immunol"},{"key":"797_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-1-62703-496-8_4","volume":"1032","author":"MM Rosado","year":"2013","unstructured":"Rosado MM, Scarsella M, Cascioli S, Giorda E, Carsetti R. Evaluating B-cells: from bone marrow precursors to antibody-producing cells. Methods Mol Biol. 2013;1032:45\u201357.","journal-title":"Methods Mol Biol"},{"key":"797_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1046\/j.1440-1754.1999.00386.x","volume":"35","author":"JM Hilton","year":"1999","unstructured":"Hilton JM, Fitzgerald DA, Cooper DM. Respiratory morbidity of hospitalized children with trisomy 21. J Paediatr Child Health. 1999;35:383\u20136.","journal-title":"J Paediatr Child Health"},{"key":"797_CR25","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00134-007-0803-z","volume":"33","author":"M Bruijn","year":"2007","unstructured":"Bruijn M, van der Aa LB, van Rijn RR, Bos AP, van Woensel JBM. High incidence of acute lung injury in children with Down syndrome. Intensive Care Med. 2007;33:2179\u201382.","journal-title":"Intensive Care Med"},{"key":"797_CR26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/archdischild-2013-304611","volume":"98","author":"R Watts","year":"2013","unstructured":"Watts R, Vyas H. An overview of respiratory problems in children with Down\u2019s syndrome. Arch Dis Child. 2013;98:812\u20137.","journal-title":"Arch Dis Child"},{"key":"797_CR27","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/INF.0000000000001243","volume":"35","author":"L Manikam","year":"2016","unstructured":"Manikam L, Reed K, Venekamp RP, Hayward A, Littlejohns P, Schilder A, Lakhanpaul M. Limited evidence on the Management of Respiratory Tract Infections in Down's syndrome: a systematic review. Pediatr Infect Dis J. 2016;35:1075\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"797_CR28","first-page":"1","volume":"59","author":"JP Nuorti","year":"2010","unstructured":"Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2010;59:1\u201318.","journal-title":"MMWR Recomm Rep"},{"key":"797_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1179\/joc.1999.11.2.126","volume":"11","author":"I La Mantia","year":"1999","unstructured":"La Mantia I, Grillo C, Mattina T, Zaccone P, Xiang M, Di Mauro M, Meroni PL, Nicoletti F. Prophylaxis with the novel immunomodulator pidotimod reduces the frequency and severity of upper respiratory tract infections in children with Down's syndrome. J Chemother. 1999;11:126\u201330.","journal-title":"J Chemother"},{"issue":"5","key":"797_CR30","first-page":"363","volume":"66","author":"A Licari","year":"2014","unstructured":"Licari A, De Amici M, Nigrisoli S, Marseglia A, Caimmi S, Artusio L, Marseglia GL. Pidotimod may prevent recurrent respiratory infections in children. Minerva Pediatr. 2014;66(5):363\u20137.","journal-title":"Minerva Pediatr"},{"key":"797_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.intimp.2018.11.043","volume":"67","author":"H Niu","year":"2019","unstructured":"Niu H, Wang R, Jia YT, Cai Y. Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: a meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019;67:35\u201345.","journal-title":"Int Immunopharmacol"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-020-0797-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13052-020-0797-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-020-0797-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:10:07Z","timestamp":1615594207000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-020-0797-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1186\/s13052-020-0797-5","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"12 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board of Bambino Ges\u00f9 Children\u2019s Hospital (No.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The local institutional review board approved the study protocol and waived the need for informed consent owing to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}